These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33446509)

  • 21. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
    Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines.
    Campain JA; Slovak ML; Schoenlein PV; Popescu NC; Gottesman MM; Pastan I
    Somat Cell Mol Genet; 1995 Nov; 21(6):451-71. PubMed ID: 8600572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
    Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
    Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
    Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
    Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y; Takano H; Fojo T
    Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.
    Sng JH; Heaton VJ; Bell M; Maini P; Austin CA; Fisher LM
    Biochim Biophys Acta; 1999 Mar; 1444(3):395-406. PubMed ID: 10095062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
    Matsumoto Y; Kunishio K; Nagao S
    J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of topoisomerase IIA (Top2α) induces telomeric DNA damage and T cell dysfunction during chronic viral infection.
    Dang X; Ogbu SC; Zhao J; Nguyen LNT; Cao D; Nguyen LN; Khanal S; Schank M; Thakuri BKC; Wu XY; Morrison ZD; Zhang J; Li Z; El Gazzar M; Ning S; Wang L; Wang Z; Moorman JP; Yao ZQ
    Cell Death Dis; 2020 Mar; 11(3):196. PubMed ID: 32193368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
    Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation.
    Guturi KKN; Bohgaki M; Bohgaki T; Srikumar T; Ng D; Kumareswaran R; El Ghamrasni S; Jeon J; Patel P; Eldin MS; Bristow R; Cheung P; Stewart GS; Raught B; Hakem A; Hakem R
    Nat Commun; 2016 Aug; 7():12638. PubMed ID: 27558965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
    Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
    Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
    Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.